---
title: "GNI Group Announces Change in Major Shareholder Following Blackstone-Linked Stake Sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296714576.md"
description: "GNI Group announced a change in major shareholders after BCP Asia AYM Holding, linked to Blackstone, reduced its stake via partial sale on August 21, 2026. The transaction is attributed to portfolio adjustment with no special business relationships, implying limited operational impact. GNI Group, a Japan-listed biopharmaceutical company, currently holds a 'Buy' rating from analysts with a Yen3800 price target."
datetime: "2026-08-23T23:52:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296714576.md)
  - [en](https://longbridge.com/en/news/296714576.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296714576.md)
generator: "portal-rs"
---

# GNI Group Announces Change in Major Shareholder Following Blackstone-Linked Stake Sale

GNI Group ( (JP:2160) ) has shared an update.

GNI Group Ltd. has reported a change in one of its major shareholders after receiving notice that BCP Asia AYM Holding (Cayman) L.P. reduced its stake to 6,541,304 shares through a partial sale on August 21, 2026. The shareholder is an exempted Cayman Islands limited partnership whose interests are indirectly held by a private equity fund managed by Blackstone, with detailed capital structure information remaining undisclosed due to confidentiality.

The company confirmed that there are no special business or capital relationships with the fund, its general partner, or any agent in Japan, indicating the transaction is a portfolio adjustment rather than a strategic shift. While the sale alters the composition of GNI Group’s major shareholders, the disclosure suggests limited immediate operational impact, but underscores ongoing private equity involvement and potential future changes in the company’s ownership profile.

The most recent analyst rating on (JP:2160) stock is a Buy  
 with a Yen3800.00 price target.  
 To see the full list of analyst forecasts on GNI Group stock,  
 see the JP:2160 Stock Forecast page. 

**More about GNI Group**

GNI Group Ltd. is a Japan-listed biopharmaceutical company on the TSE Growth market, developing and commercializing pharmaceutical products. The group focuses on innovative therapies, leveraging global investment partnerships to support its operations and growth strategy in the healthcare sector.

**YTD Price Performance:** 15.51%

**Average Trading Volume:** 1,098,815

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** Yen183.4B

### Related Stocks

- [2160.JP](https://longbridge.com/en/quote/2160.JP.md)
- [BX.US](https://longbridge.com/en/quote/BX.US.md)

## Related News & Research

- [Haverford Trust Co Buys Shares of 7,562 Blackstone Inc. $BX](https://longbridge.com/en/news/296700047.md)
- [Blackstone transformed Jersey Mike's. Now it's giving employees a bite of the $7 billion IPO.](https://longbridge.com/en/news/294332024.md)
- [Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296585791.md)
- [Broadcom CDS Explodes As It Seeks Up To $100 Billion In Massive Off-Balance Sheet Debt Deal](https://longbridge.com/en/news/296560520.md)
- [Ocugen to Participate in Upcoming September Investor and Industry Conferences | OCGN Stock News](https://longbridge.com/en/news/296903578.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**